Emerging Stocks Down Under 15 February 2022: Cyclopharm (ASX:CYP)

Cyclopharm: Will the wait for FDA approval be worth it?

In today’s edition of Emerging Stocks Down Under, we look at Cyclopharm, the ASX company that is responsible for Technegas – a gas-like, radioactive compound that is delivered throughout the pathways of a lung, allowing a gamma camera to create a functional ventilation image of the lung and diagnose problems with the lung. Technegas is sold in 60 countries around the world but the United States isn’t one of them and the company has spent years trying to gain approval.

Cyclopharm shares dropped last month after it told shareholders, Technegas wouldn’t be approved by the FDA until at least early 2023. Can shareholders be confident that FDA approval will happen then and will the wait be worth it?

Click here to read the previous edition of Emerging Stocks Down Under published 8 February 2022

For in-depth research reports or to keep up-to-date on the latest Stocks Down Under news see our parent company, Pitt Street Research, or follow us on Facebook and Twitter.